Skip to main content
Top
Published in: Digestive Diseases and Sciences 4/2024

21-02-2024 | Pancreatic Cancer | Original Article

Epidemiology and Socioeconomic Impact of Pancreatic Cancer: An Analysis of the Global Burden of Disease Study 1990–2019

Authors: Daryl Ramai, Eric R. Smith, Yichen Wang, Yuting Huang, Itegbemie Obaitan, Saurabh Chandan, Banreet Dhindsa, Apostolis Papaefthymiou, John D. Morris

Published in: Digestive Diseases and Sciences | Issue 4/2024

Login to get access

Abstract

Introduction

The aim of this study is to estimate the global burden of pancreatic cancer from 1990 to 2019.

Methods

We reconstructed the Global Burden of Diseases (GBD) study results for pancreatic cancer across 204 countries and territories. Our study generated estimates for key disease burden indicators, including incidence, prevalence, mortality, and disability-adjusted life years (DALYs), and cost. Linear regression analysis of the natural logarithm of age-standardized outcomes was used to calculate annual percent change.

Results

In 2019, there were a total of 530,296 incident and 442,101 prevalent cases of pancreatic cancer, resulting in 531,107 deaths and 11.5 million DALYs lost. The age-standardized incidence and prevalence of pancreatic cancer has increased from 5.22 (95% CI 4.97–5.40) to 6.57 (CI 6.00–7.09) per 100,000 people per year, and 4.1 (95% CI 3.95–4.26) to 5.4 (CI 4.96–5.87), respectively. This equated to 10 million (95% CI 9.5 to 10.4 million) incident cases of pancreatic cancer. The number of DALYs lost as a result of pancreatic cancer was 225 million years (95% CI 216–234 million years). Mortality from pancreatic cancer increased over the study period from 3.7 (95% CI 3.54–3.83) to 6.9 (95% CI 6.36–7.32). Incidence, prevalence, DALYs, and mortality were higher in countries with a higher socio-demographic index.

Conclusions

Pancreatic cancer is rising around the world and is associated with a high economic burden. Programs aimed at reducing modifiable risk factors are needed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249.CrossRefPubMed Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–249.CrossRefPubMed
2.
go back to reference Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493–502.CrossRefPubMedPubMedCentral Klein AP. Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 2021;18:493–502.CrossRefPubMedPubMedCentral
4.
go back to reference Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159:358–62.CrossRefPubMed Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159:358–62.CrossRefPubMed
5.
6.
7.
go back to reference Ali H, Pamarthy R, Vallabhaneni M, et al. Pancreatic cancer incidence trends in the United States from 2000–2017: Analysis of Surveillance, Epidemiology and End Results (SEER) database. F1000Research. F1000Res. 2021;10:529. Ali H, Pamarthy R, Vallabhaneni M, et al. Pancreatic cancer incidence trends in the United States from 2000–2017: Analysis of Surveillance, Epidemiology and End Results (SEER) database. F1000Research. F1000Res. 2021;10:529.
8.
go back to reference GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222.
9.
go back to reference GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–266. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–266.
15.
go back to reference Bennitt FB, Wozniak SS, Causey K et al. Estimating disease burden attributable to household air pollution: new methods within the Global Burden of Disease Study. The Lancet Global Health. 2021;9:S18.CrossRef Bennitt FB, Wozniak SS, Causey K et al. Estimating disease burden attributable to household air pollution: new methods within the Global Burden of Disease Study. The Lancet Global Health. 2021;9:S18.CrossRef
16.
go back to reference Peterson HM, Flaxman AD. Meta-regression with DisMod-MR: how robust is the model? The Lancet. 2013;381:S110.CrossRef Peterson HM, Flaxman AD. Meta-regression with DisMod-MR: how robust is the model? The Lancet. 2013;381:S110.CrossRef
17.
go back to reference G Gordon-Dseagu VL, Devesa SS, Goggins M, et al. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427–39. G Gordon-Dseagu VL, Devesa SS, Goggins M, et al. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018;47:427–39.
19.
go back to reference Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55:1158–1160.CrossRefPubMed Ferlay J, Partensky C, Bray F. More deaths from pancreatic cancer than breast cancer in the EU by 2017. Acta Oncol. 2016;55:1158–1160.CrossRefPubMed
20.
go back to reference Wang Y, Huang Y, Chase RC, et al. Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019 [published online ahead of print, 2023 Jun 9]. Gastroenterology. 2023;S0016–5085:00825–9. Wang Y, Huang Y, Chase RC, et al. Global Burden of Digestive Diseases: A Systematic Analysis of the Global Burden of Diseases Study, 1990 to 2019 [published online ahead of print, 2023 Jun 9]. Gastroenterology. 2023;S0016–5085:00825–9.
21.
go back to reference Ramai D, Lanke G, Lai J, et al. Early- and late-onset pancreatic adenocarcinoma: A population-based comparative study. Pancreatology. 2021;21:124–129. CrossRefPubMed Ramai D, Lanke G, Lai J, et al. Early- and late-onset pancreatic adenocarcinoma: A population-based comparative study. Pancreatology. 2021;21:124–129. CrossRefPubMed
22.
go back to reference Abboud Y, Samaan JS, Oh J et al. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001–2018. Gastroenterology. 2023;164:978-989.e6.CrossRefPubMed Abboud Y, Samaan JS, Oh J et al. Increasing Pancreatic Cancer Incidence in Young Women in the United States: A Population-Based Time-Trend Analysis, 2001–2018. Gastroenterology. 2023;164:978-989.e6.CrossRefPubMed
23.
go back to reference Piciucchi M, Capurso G, Valente R et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15:151–155.CrossRefPubMed Piciucchi M, Capurso G, Valente R et al. Early onset pancreatic cancer: risk factors, presentation and outcome. Pancreatology. 2015;15:151–155.CrossRefPubMed
24.
go back to reference Liu J, Ren ZH, Qiang H et al. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20:1415.CrossRefPubMedPubMedCentral Liu J, Ren ZH, Qiang H et al. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. BMC Public Health. 2020;20:1415.CrossRefPubMedPubMedCentral
25.
go back to reference Prabhakaran D, Chaturvedi V, Shah P et al. Differences in the prevalence of metabolic syndrome in urban and rural India: a problem of urbanization. Chronic Illn. 2007;3:8–19.CrossRefPubMed Prabhakaran D, Chaturvedi V, Shah P et al. Differences in the prevalence of metabolic syndrome in urban and rural India: a problem of urbanization. Chronic Illn. 2007;3:8–19.CrossRefPubMed
26.
go back to reference Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209.CrossRefPubMed Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:197–209.CrossRefPubMed
27.
go back to reference World Health Organization. WHO global report on trends in prevalence of tobacco smoking 2000–2025. World Health Organization, 2018. World Health Organization. WHO global report on trends in prevalence of tobacco smoking 2000–2025. World Health Organization, 2018.
28.
go back to reference Bilano V, Gilmour S, Moffiet T et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control [published correction appears in Lancet. 2015 Jun 13;385:2354]. Lancet 2015;385:966–976.CrossRefPubMed Bilano V, Gilmour S, Moffiet T et al. Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control [published correction appears in Lancet. 2015 Jun 13;385:2354]. Lancet 2015;385:966–976.CrossRefPubMed
29.
go back to reference Overbeek KA, Levink IJ, Koopmann BD et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71:1152–1160.CrossRefPubMed Overbeek KA, Levink IJ, Koopmann BD et al. Long-term yield of pancreatic cancer surveillance in high-risk individuals. Gut. 2022;71:1152–1160.CrossRefPubMed
31.
go back to reference Fan KM, Rimal J, Zhang P et al. Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications. EClinicalMedicine. 2022;54:101673.CrossRefPubMedPubMedCentral Fan KM, Rimal J, Zhang P et al. Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications. EClinicalMedicine. 2022;54:101673.CrossRefPubMedPubMedCentral
Metadata
Title
Epidemiology and Socioeconomic Impact of Pancreatic Cancer: An Analysis of the Global Burden of Disease Study 1990–2019
Authors
Daryl Ramai
Eric R. Smith
Yichen Wang
Yuting Huang
Itegbemie Obaitan
Saurabh Chandan
Banreet Dhindsa
Apostolis Papaefthymiou
John D. Morris
Publication date
21-02-2024
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2024
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08292-1

Other articles of this Issue 4/2024

Digestive Diseases and Sciences 4/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine